Abstract Next Generation Sequencing (NGS) has dramatically improved the flexibility and
outcomes of cancer research and clinical trials, providing highly sensitive and accurate high …

Accurate assessment of TP53 gene status in sporadic tumors and in the germline of
individuals at high risk of cancer due to Li–Fraumeni Syndrome (LFS) has important clinical …

Purpose: The prevalence of mutations in cancer susceptibility genes such as BRCA1 and
BRCA2 and other cancer susceptibility genes and their clinical relevance are largely …

The prevalence of germ line mutations in non‐BRCA 1/2 genes associated with hereditary
breast cancer (BC) is low, and the role of some of these genes in BC predisposition and …

Understanding the gene-specific risks for development of breast cancer will lead to
improved clinical care for those carrying germline mutations in cancer predisposition genes …

Genetic testing for hereditary cancer predisposition has evolved rapidly in recent years with
the discovery of new genes, but there is much debate over the clinical utility of testing genes …

Purpose Integration of gene panels in the diagnosis of hereditary breast and ovarian cancer
(HBOC) requires a careful evaluation of the risk associated with pathogenic or likely …

Soon after the discovery of BRCA1 and BRCA2 over 20 years ago, it became apparent that
not all hereditary breast and/or ovarian cancer syndrome families were explained by …

Answer questions and earn CME/CNE Fifteen percent of women with epithelial ovarian
cancer have inherited mutations in the BRCA breast cancer susceptibility genes. Knowledge …

Purpose Several genes on hereditary breast and ovarian cancer susceptibility test panels
have not been systematically examined for strength of association with disease. We …